Analysis of historical negative control group data from the rat in vivo micronucleus assay.


Journal

Mutation research. Genetic toxicology and environmental mutagenesis
ISSN: 1879-3592
Titre abrégé: Mutat Res Genet Toxicol Environ Mutagen
Pays: Netherlands
ID NLM: 101632149

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 08 07 2019
revised: 22 08 2019
accepted: 24 08 2019
entrez: 24 2 2020
pubmed: 24 2 2020
medline: 23 4 2020
Statut: ppublish

Résumé

A database of micronuclei counts for historical negative control data from rat in vivo micronuclei tests performed in 10 different laboratories was established. Data were available from over 4000 negative control rats from 10 laboratories. The mean frequency of micronucleated cells (MN)/1000 cells ranged from 0.44 to 2.22, a 5-fold range. Overall there were no major sex or strain differences in frequency, although there were some small but statistically significant differences within laboratories. There was appreciable variability between experiments compared with variability within experiments in some laboratories. No specific factor was identified which could explain this variability although it was noted that many different vehicles were used in the experiments. It is hoped that these data will help laboratories beginning studies with the rat micronucleus assay and those involved in the assessment of micronucleus assay results.

Identifiants

pubmed: 32087845
pii: S1383-5718(19)30227-X
doi: 10.1016/j.mrgentox.2019.503086
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

503086

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

D P Lovell (DP)

St George's Medical School, University of London, Cranmer Terrace, London, SW17 0RE, UK. Electronic address: dlovell@sgul.ac.uk.

M Fellows (M)

Astra Zeneca, Drug Safety and Metabolism, Cambridge, CB4 0WG, UK.

J Saul (J)

Covance Laboratories, Harrogate, North Yorkshire, HG3 1PY, UK.

J Whitwell (J)

Covance Laboratories, Harrogate, North Yorkshire, HG3 1PY, UK.

L Custer (L)

Bristol-Myers Squibb, New Brunswick, NJ, USA.

S Dertinger (S)

Litron Laboratories, Rochester, NY, USA.

P Escobar (P)

Merck Co. & Inc., West Point, PA, USA.

R Fiedler (R)

Covance Laboratories, Greenfield, IN, USA.

U Hemmann (U)

Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.

J Kenny (J)

GlaxoSmithKline, Ware, Hertfordshire, UK.

R Smith (R)

Covance Laboratories, Harrogate, North Yorkshire, HG3 1PY, UK.

B M van der Leede (BM)

Janssen R&D, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium.

A Zeller (A)

Pharmaceutical Sciences, pRED Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH